• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2,9-二芳基-6,13-双(三异丙基甲硅烷基乙炔基)并五苯衍生物:合成及其在癌症声动力治疗中的应用

2,9-Diaryl-6,13-bis(triisopropylsilylethynyl)pentacene derivatives: synthesis and application in cancer sonodynamic therapy.

作者信息

Han Nan, Hou Chunyuan, Duan Zhuofei, Gu Jun, Zhang Yu, Luo Jun

机构信息

School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.

出版信息

Chem Commun (Camb). 2025 Mar 27;61(27):5174-5177. doi: 10.1039/d5cc00326a.

DOI:10.1039/d5cc00326a
PMID:40071295
Abstract

Four 2,9-aryl substituted 6,13-bis(triisopropylsilylethynyl)pentacene derivatives were synthesized as sonosensitizers. Their extensive delocalized π-electron conjugation system facilitated the generation of reactive oxygen species (ROS) under ultrasound irradiation. Therapeutic results validate that the as-prepared compounds have significant advantages in sonodynamic therapy.

摘要

合成了四种2,9-芳基取代的6,13-双(三异丙基甲硅烷基乙炔基)并五苯衍生物作为声敏剂。它们广泛的离域π电子共轭体系有助于在超声照射下产生活性氧(ROS)。治疗结果证实,所制备的化合物在声动力治疗中具有显著优势。

相似文献

1
2,9-Diaryl-6,13-bis(triisopropylsilylethynyl)pentacene derivatives: synthesis and application in cancer sonodynamic therapy.2,9-二芳基-6,13-双(三异丙基甲硅烷基乙炔基)并五苯衍生物:合成及其在癌症声动力治疗中的应用
Chem Commun (Camb). 2025 Mar 27;61(27):5174-5177. doi: 10.1039/d5cc00326a.
2
Novel 131-iodine labeled and ultrasound-responsive nitric oxide and reactive oxygen species controlled released nanoplatform for synergistic sonodynamic/nitric oxide/chemodynamic/radionuclide therapy.新型 131 碘标记的超声响应型一氧化氮和活性氧控制释放纳米平台用于协同声动力/一氧化氮/化学动力学/放射性核素治疗。
Bioorg Chem. 2024 Sep;150:107593. doi: 10.1016/j.bioorg.2024.107593. Epub 2024 Jun 28.
3
Synthesis of porphyrin-incorporating covalent organic frameworks for sonodynamic therapy.含卟啉的共价有机框架的超声动力治疗合成。
Chem Commun (Camb). 2021 Aug 25;57(66):8178-8181. doi: 10.1039/d1cc02902a. Epub 2021 Jul 27.
4
Defect-rich sonosensitizers based on CeO with Schottky heterojunctions for boosting sonodynamic/chemodynamic synergistic therapy.基于具有肖特基异质结的富缺陷 CeO 的声敏剂用于增强声动力/化学动力学协同治疗。
J Mater Chem B. 2024 May 1;12(17):4162-4171. doi: 10.1039/d4tb00084f.
5
Metallized hollow-COF nanobowls with dual-mode ROS generation for cancer sonodynamic therapy.用于癌症声动力治疗的具有双模式活性氧生成的金属化中空共价有机框架纳米碗
J Mater Chem B. 2025 May 1;13(17):5181-5189. doi: 10.1039/d5tb00338e.
6
Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.声动力疗法联合 PI-103 对肝癌的协同抗癌策略。
Drug Des Devel Ther. 2021 Feb 11;15:531-542. doi: 10.2147/DDDT.S296880. eCollection 2021.
7
Synthesis of New Bis-Spiropyrazoles as Antitumor Agents under Ultrasound Irradiation.超声辐射下新型双螺吡唑类化合物作为抗肿瘤剂的合成
Mini Rev Med Chem. 2018;18(7):631-637. doi: 10.2174/1389557517666170912170027.
8
Piezoelectric-mediated two-dimensional copper-based metal-organic framework for synergistic sonodynamic and cuproptosis-driven tumor therapy.压电介导的二维铜基金属有机框架用于协同声动力学和铜死亡驱动的肿瘤治疗。
J Colloid Interface Sci. 2025 Feb;679(Pt B):354-363. doi: 10.1016/j.jcis.2024.10.108. Epub 2024 Oct 20.
9
Phytochlorin-Based Sonosensitizers Combined with Free-Field Ultrasound for Immune-Sonodynamic Cancer Therapy.基于二氢卟吩的声敏剂联合自由场超声用于免疫声动力癌症治疗
Adv Mater. 2025 Feb;37(8):e2410559. doi: 10.1002/adma.202410559. Epub 2025 Jan 12.
10
Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.新型噻唑取代双吡唑啉肟衍生物的设计、合成及通过选择性诱导癌细胞凋亡和 ROS 产生的抗肿瘤活性的生物评价。
Med Chem. 2019;15(7):743-754. doi: 10.2174/1573406414666180827112724.

引用本文的文献

1
Tumor Treating Fields and Combination Therapy in Management of Brain Oncology.肿瘤治疗电场与联合疗法在脑肿瘤治疗中的应用
Cancers (Basel). 2025 Apr 2;17(7):1211. doi: 10.3390/cancers17071211.